Alpha Cognition Reports Strong ZUNVEYL Commercial Growth in Q3 2025
Alpha Cognition Inc. demonstrates accelerating commercial momentum for its Alzheimer's treatment ZUNVEYL with 102% sequential pharmacy order growth and expanding reach across more than 600 nursing homes, positioning the company for sustained growth and potential profitability by 2027.
Read the full story


























